Bausch Health Companies Inc. and its Salix Pharmaceuticals Ltd. unit agreed with Teva Pharmaceuticals USA Inc. to resolve litigation relating to the extended-release formulation of Apriso.
Apriso, or mesalamine, is used to treat inflammatory bowel disease ulcerative colitis in adults.
As part of the agreement, Bausch will grant Teva a nonexclusive license to market a generic version of the drug in the U.S., starting Oct. 1, 2021, and it will not make any financial payments or other transfers.
The patent for Apriso is set to expire in 2030.
Bausch, which acquired the rights to Apriso through its acquisition of Salix in April 2015, said it will continue to vigorously defend its intellectual property.
Bausch also modified its prior sub-license agreement for the drug with Lupin Pharmaceuticals Inc.